Is Lactate Dehydrogenase (LDH) a biomarker for hemolysis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 25, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

LDH as a Biomarker for Hemolysis

Yes, lactate dehydrogenase (LDH) is a well-established biomarker for hemolysis, though it lacks specificity and should be interpreted alongside other laboratory findings.

Role of LDH in Hemolysis Detection

LDH is released during the breakdown of red blood cells and serves as a key indicator of hemolytic processes. According to the American Society of Hematology guidelines, LDH is specifically mentioned as one of the diagnostic criteria for delayed hemolytic transfusion reactions (DHTR) in sickle cell disease 1. When evaluating for hemolysis, LDH elevation is typically accompanied by:

  • Decreased hemoglobin levels
  • Reduced haptoglobin
  • Elevated bilirubin
  • Presence of schistocytes in peripheral blood smear
  • Negative direct and indirect Coombs tests (in non-immune hemolysis)

LDH Isoenzymes in Hemolysis

The specificity of LDH for hemolysis is enhanced by examining its isoenzyme pattern:

  • LDH1 and LDH2 are the predominant isoforms in erythrocytes 2
  • In true hemolytic conditions, these isoenzymes are disproportionately elevated
  • Isoenzyme fractionation can confirm the erythrocyte origin of elevated LDH 2

Limitations of LDH as a Hemolysis Marker

Despite its utility, LDH has important limitations:

  • Lack of specificity: LDH is present in many tissues and can be elevated in various conditions including:

    • Myocardial infarction
    • Liver disease
    • Malignancies (especially testicular cancer and melanoma) 1, 3
    • Muscle injury
    • Pulmonary disease
  • Normal LDH in hemolysis: Some cases of autoimmune hemolytic anemia (AIHA) present with normal LDH levels despite other evidence of hemolysis 4. Studies have shown that up to 25% of AIHA cases may have normal LDH levels.

  • Non-hemolytic sources in conditions with hemolysis: In thrombotic thrombocytopenic purpura (TTP), a condition associated with microangiopathic hemolysis, research has shown that LDH elevation may be predominantly from damaged tissues rather than from hemolyzed erythrocytes 5.

Clinical Application

When using LDH to evaluate for hemolysis:

  1. Always interpret in context with other hemolytic markers:

    • Decreased hemoglobin
    • Reduced haptoglobin (more specific for hemolysis)
    • Elevated indirect bilirubin
    • Reticulocytosis
    • Presence of schistocytes
  2. Serial measurements are more valuable than single readings 6, 7

  3. Consider LDH isoenzyme fractionation when the source of LDH elevation is unclear

  4. Be aware of baseline elevation in certain conditions like sickle cell disease where chronic hemolysis may lead to persistently elevated LDH 2

Threshold Values

  • LDH >2.5 times the upper limit of normal is often used as a threshold for significant hemolysis in various clinical contexts 7
  • In mechanical circulatory support settings, an increase in plasma-free hemoglobin (>40 mg/dL) may be more specific for hemolysis than LDH changes 6

In summary, while LDH is a valuable biomarker for hemolysis, it should be interpreted as part of a comprehensive panel of hemolytic markers rather than in isolation due to its limited specificity.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.